First Medication for Severe Frostbite;

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

FDA Approves Eli Lilly’s AD Drug Ebglyss (Lebrikizumab)
FDA Approves Eli Lilly’s AD Drug Ebglyss (Lebrikizumab)
DermWire TV
FDA Approves Eli Lilly’s AD Drug Ebglyss (Lebrikizumab)
NIH Analysis Examines Association Between AD and Comorbidities
NIH Analysis Examines Association Between AD and Comorbidities
DermWire TV
NIH Analysis Examines Association Between AD and Comorbidities
Study Examines Association Between Childhood BMI and Risk of Developing IMSDs
Study Examines Association Between Childhood BMI and Risk of Developing IMSDs
DermWire TV
Study Examines Association Between Childhood BMI and Risk of Developing IMSDs
FDA Approves New Drug for Prurigo Nodularis; Long-Term Use of Dupilumab Examined
FDA Approves New Drug for Prurigo Nodularis; Long-Term Use of Dupilumab Examined
DermWire TV
FDA Approves New Drug for Prurigo Nodularis; Long-Term Use of Dupilumab Examined

First Medication for Severe Frostbite; Biosimilar to Humira with Interchangeability Status Approved; Two Late-Stage AD Candidates Advance